https://www.businesswire.com/news/home/20241101923447/en/Oncoinvent-Announces-Publication-of-18-Month-Safety-and-Efficacy-Data-from-the-Phase-12a-Study-of-Radspherin-in-Colorectal-Cancer
Oncoinvent Announces Publication of 18-Month Safety and Efficacy Data from the Phase 1/2a Study of...
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced the publication of data from the P...
https://finanza.repubblica.it/Company/?symbol=0RU5:LN
Oncoinvent ASA - Scheda - Economia e Finanza - Repubblica.it
0RU5:LN: ultimo valore, variazione, variazione percentuale, beta, grafico, ultime notizie
economia e finanzaasaschedarepubblica
https://www.prnewswire.com/news-releases/oncoinvent-asa-second-half-2025-results-302697978.html
Oncoinvent ASA: Second half 2025 results
/PRNewswire/ -- Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the...
second halfasaresults